United Therapeutics
Logotype for United Therapeutics Corporation

United Therapeutics (UTHR) investor relations material

United Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for United Therapeutics Corporation
Jefferies Global Healthcare Conference summary17 Nov, 2026

Commercial performance and outlook

  • Q3 revenue reached a record $833 million; TYVASO revenue also set a record at $504 million.

  • More than 1,000 referrals across the commercial portfolio in October set a new monthly record; management expects added sales teams to support Q4 and 2027 momentum.

TYVASO in PH-ILD

  • PH-ILD remains a key growth driver; management expects newly diagnosed patients to transition to TYVASO DPI as the settlement’s label and communication changes take effect, with momentum expected in Q4 and 2027.

  • Timing of payer coverage changes will vary by payer; management hopes updates align with the beginning-of-year reauthorization process.

  • Management plans close monitoring of settlement compliance and said it would act to protect its intellectual property if the agreed guardrails are not followed.

  • Management expressed comfort with current rebates but said it would assess the settlement’s prospective gross-to-net impact over time.

TYVASO in IPF

  • The FDA accepted the nebulized TYVASO sNDA for IPF, with a PDUFA date of April 26; management expects broad use and does not anticipate a price change.

  • TETON results were described as generalizable across subgroups and on background therapy; use could be adjunctive, refractory, or potentially first-line, guided by physician judgment and patient needs.

  • Payer discussions and Medicare local coverage determination work are ongoing; teams are preparing, with further progress expected in 2027 as the PDUFA date approaches.

  • European partner Ferrer filed with the EMA for nebulized TYVASO in IPF in the regions covered by its agreement.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next United Therapeutics earnings date

Logotype for United Therapeutics Corporation
Q4 202624 Feb, 2027
United Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next United Therapeutics earnings date

Logotype for United Therapeutics Corporation
Q4 202624 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

United Therapeutics Corporation is a biotechnology company specializing in the development and commercialization of therapies to address chronic and life-threatening conditions. The company focuses on treatments for pulmonary arterial hypertension (PAH) and other cardiovascular and respiratory diseases. Its portfolio includes pharmaceutical products and delivery systems designed to improve patient outcomes and quality of life. The company is headquartered in Silver Spring, Maryland, and its shares are listed on the NASDAQ Stock Exchange.